ENMD-2076, with the CAS number 934353-76-1, is a small molecule that has been investigated primarily for its potential therapeutic applications, particularly in the field of oncology. It is classified as a selective inhibitor of certain kinases, which play crucial roles in cell signaling pathways that regulate cell growth and proliferation. The compound has shown promise in preclinical studies for its ability to inhibit tumor growth and induce apoptosis in cancer cells. ENMD-2076 is characterized by its specific binding affinity to target kinases, which may contribute to its efficacy in disrupting cancer cell signaling. Additionally, it has been evaluated for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for determining its suitability as a therapeutic agent. As with many investigational drugs, ongoing research aims to further elucidate its mechanism of action, optimize its formulation, and assess its safety and effectiveness in clinical settings.

ENMD-2076

934353-76-1: ENMD-2076, with the CAS number 934353-76-1, is a small molecule that has been investigated primarily for its potential therapeutic applications, particularly in the field of oncology. It is classified as a selective inhibitor of certain kinases, which play crucial roles in cell signaling pathways that regulate cell growth and proliferation. The compound has shown promise in preclinical studies for its ability to inhibit tumor growth and induce apoptosis in cancer cells. ENMD-2076 is characterized by its specific binding affinity to target kinases, which may contribute to its efficacy in disrupting cancer cell signaling. Additionally, it has been evaluated for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for determining its suitability as a therapeutic agent. As with many investigational drugs, ongoing research aims to further elucidate its mechanism of action, optimize its formulation, and assess its safety and effectiveness in clinical settings.

<p>ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.</p>

CAS 934353-76-1

ENMD-2076

ENMD-2076

Ref: IN-DA00GU36

ENMD-2076

Ref: 54-BUP03265

ENMD-2076

Ref: TM-T2358